Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 197 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Nephropathy Clear all
Active, not recruiting Phase 4 Interventional

Pentoxifylline in Diabetic Kidney Disease

NCT03625648
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

NCT02545049
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
173
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Jul 21, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

NCT04387448
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 21, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)

NCT01829256
View directory record Official record
Conditions
Diabetes, Hypertension, Diabetic Kidney Disease
Interventions
Pharmacist telehealth intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Angiotensin II Antagonism of TGF-Beta 1

NCT00320970
View directory record Official record
Conditions
Diabetic Nephropathy, Hypertension
Interventions
Candesartan
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

NCT00664027
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
RTA 402 (Bardoxolone Methyl)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

NCT02552277
View directory record Official record
Conditions
Diabetic Nephropathies, Peripheral Nervous System Diseases
Interventions
PDA-002, Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Garden Grove, California • Orange, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

NCT03804879
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Nidufexor, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 21, 2026, 10:04 AM EDT
Terminated Phase 1 Interventional

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

NCT03840343
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions
Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 21, 2026, 10:04 AM EDT
Terminated Phase 3 Interventional

Pyridorin in Diabetic Nephropathy

NCT02156843
View directory record Official record
Conditions
Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
Pyridorin, Placebo
Drug
Lead sponsor
NephroGenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

NCT00446459
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Jul 21, 2026, 10:04 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

NCT03502031
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Interventions
Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Drug
Lead sponsor
James A. Tumlin, MD
Other
Eligibility
75 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Lawrenceville, Georgia • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 21, 2026, 10:04 AM EDT
Enrolling by invitation Not applicable Interventional

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

NCT05514184
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions
PLAFOND diet
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Orange, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Metabolism of Low Carbohydrate and Ketogenic Diet

NCT05071287
View directory record Official record
Conditions
Diabetic Kidney Disease, Cognitive Function, Weight Loss, Diabetic Control, Type2 Diabetes
Interventions
mHealth + low-fat diet, mHealth + low-carb/ketogenic diet
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 21, 2026, 10:04 AM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product

NCT06790498
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

NCT01265563
View directory record Official record
Conditions
Diabetic Nephropathy, Proteinuria, Oxidative Stress
Interventions
N-acetylcysteine placebo and silibin placebo, N-acetylcysteine active and silibin placebo, N-acetylcysteine placebo and silibin active, N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 76 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Jul 21, 2026, 10:04 AM EDT
Recruiting Phase 4 Interventional

Mechanism of SGLT2 Inhibition in the Kidney

NCT06291155
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Kidney Disease
Interventions
SGLT2 inhibitor
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 21, 2026, 10:04 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes

NCT01307917
View directory record Official record
Conditions
Diabetic Nephropathy, Endothelial Dysfunction
Interventions
flavonoids
Dietary Supplement
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
12 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jul 21, 2026, 10:04 AM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

NCT02010242
View directory record Official record
Conditions
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions
GKT137831, Placebo
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Orange, California • Coral Gables, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 21, 2026, 10:04 AM EDT
Not yet recruiting No phase listed Observational

Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients

NCT06101901
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 21, 2026, 10:04 AM EDT